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Background
The most promising immunotherapeutics tested in meta-
static melanoma patients are the monoclonal antibody
blocking CTLA-4 (Ipilimumab), and those interfering
with PD-1 and PD-L1. However, the lack of knowledge
on predictive biomarkers that could assist the treatment
remains a limiting factor. We speculate that, along with
additional markers, the immunoscore [1] is fundamental
as prognostic and predictive marker for response to
immunotherapies in metastatic melanoma. Our previous
data demonstrate that NK cells control the melanoma
progression [2,3]. Therefore we have analysed both
T cells and NK cells subsets frequencies and receptors
repertoire in the peripheral blood of Ipilimumab treated
patients with Stage IV metastatic melanoma.
Material and methods
Peripheral blood mononuclear cells (PBMCs) from 12
different patients with stage IV metastatic melanoma
were collected and analyzed. Each patient received 4
infusions of Ipilimumab each 21 days. Before each infu-
sion we collected patients’ blood and isolated PBMCs to
analyze the lymphocytes compartment.
We stained for the following antibodies: CD56 PE, CD3
Fitc, CD56 APC, CD4 PeCy7, CD8 APCCy7, CD152
(CTLA4) PE, CD279 (PD-1) PE, CCR7 PeCy7, CD158a/h
(KIR2DL1/S1) PE, CD158b (KIR2DL2/DL3) PE, CD158e
(KIR3DL1) PE, CD16 APCCy7, CD57 PE, CD69 PE,
CD314 (NKG2D) PE, CD226 (DNAM-1) PE, CD337
(NKp30) PE, CD336 (NKp44) PE, CD335 (NKp46) PE
(Miltenyi Biotech), CD192 (CCR2) AlexaFluor 647,
CXCR2 (IL8RB) APC, 7-AADStaining Solution (BD Ita-
lia), TIM3 PE (ebioscience), NKG2C PE (R&D Systems).
The analysis was performed with FACS CANTO II.
Statistical analysis was performed with Anova and
Student’s t-test.
Results
Our data indicate that, after the first Ipilimumab treat-
ment, an inversion of CD4/CD8 ratio occurs with a conco-
mitant increase in the CD56dim population and a higher
expression of TIM-3 and NKp46 molecules on the surface
of NK cells. Moreover, the frequency of NK and T cells
expressing KIRs and CCR7 is reduced, while the mean
fluorescence intensity of CD16 and PD1 is upregulated on
both CD56bright and CD56dim NK cells.
Conclusions
These preliminary data indicate that early during Ipilimu-
mab treatment, cytotoxic lymphocytes CD8+ T cells and
CD56dim NK cells expand and become activated. NK
cells seem to be polarized towards a CD56dimCD16bright
KIRs+NKp46+TIM3+ phenotype. Ipilimumab treatment
may induce NK cells maturation, which might in turn
drive activation of CD8+ T cells.
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